Add BrightSurf on Google Email

Modified adenovirus offers new approach to treating aggressive brain tumors

A modified adenovirus, Delta-24-RGD, has shown improved infectivity and replication efficiency compared to the unmodified Delta-24. This leads to increased cytopathic effects and prolonged survival rates in mouse models of human glioma. The authors conclude that Delta-24-RGD may be an effective agent in treating gliomas.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateMay 6, 2003

Common thyroid cancer gene mutation found

Researchers at Johns Hopkins Medicine discovered a BRAF gene mutation in 68% of papillary thyroid cancers, which can be challenging to distinguish from benign conditions. This mutation causes continuous cell growth and division, leading to cancer.

SourceJohns Hopkins Medicine·JournalJNCI Journal of the National Cancer Institute·DateApr 15, 2003

Physics tip sheet #34 - April 1, 2003

Researchers are investigating new methods to combat cancer growth through computer models and cytotoxic treatments. They also discovered that a process called Auger emission can cause electrons to be emitted in well-defined directions by single molecules, leading to potential breakthroughs in physics research.

SourceAmerican Physical Society·JournalPhysical Review Letters·DateApr 1, 2003

Neurofibromin: It's so degrading

The discovery of neurofibromin regulation may help develop targeted therapies to block neurofibromin degradation in NF1 patients and treat cancers with amplified Ras activity. Nf1 heterozygous cells show increased sensitivity to growth factors, suggesting even diminished neurofibromin levels can affect normal cell behavior.

SourceCold Spring Harbor Laboratory·JournalGenes & Development·DateFeb 5, 2003

JCI Table of Contents, January 2, 2003

Researchers found that nicotine stimulates lung epithelial cells to activate a molecular pathway promoting cell growth and survival. This activation undermines the body's natural defense mechanism against cancer. The study suggests reconsidering the risk-benefit ratio of nicotine-based quitting aids.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateJan 2, 2003

Nicotine - Worse than we thought?

Research reveals nicotine activates Akt survival pathway, undermining programmed cell death in lung cancer cells. This finding may lead to re-evaluation of quitting-aids' benefits.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateJan 2, 2003

Combination hormone therapy associated with increase in breast density

A recent study published in the Journal of the National Cancer Institute found that combination hormone therapy was associated with a 3-5% increase in breast density, while estrogen alone had no effect. This suggests that increased breast density may be a valid marker for the effect of interventions on breast cancer risk.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateDec 31, 2002

Statins benefit older people

A recent study found that pravastatin treatment reduced coronary death, non-fatal heart attack, and fatal or non-fatal stroke by 15% in adults aged 70-82. The benefits were most pronounced for reducing death from heart disease, with a nearly 25% relative risk reduction.

SourceThe Lancet_DELETED·JournalThe Lancet·DateNov 21, 2002

Health care rationing in Germany

A study analyzing patient deaths and survivors in German hospitals found that nearly 40% of total expenditures went towards the care of just 10% of patients. The most expensive group were young female cancer patients, while old and terminally ill patients accounted for the lowest costs.

SourceMax-Planck-Gesellschaft·JournalSocial Science & Medicine·DateNov 11, 2002

Researchers track elusive brain tumor cells in mice with neural stem cells modified to deliver IL-12

Scientists have developed a novel treatment using neural stem cells to track and target brain tumor cells that spread into normal brain tissue. The therapy involves genetically engineering neural stem cells to produce interleukin 12, an immune-stimulating chemical known to kill glioma cells. Mice treated with this approach survived sig...

SourceCedars-Sinai Medical Center·JournalCancer Research·DateOct 15, 2002

New avenue of HIV damage found

Researchers have found a new avenue of HIV damage that affects the structure of CD4 T cells, making it impossible for them to function normally. This discovery may lead to improved disease staging and therapy, as therapies targeting inflammation and scar tissue accumulation could enhance current antiviral treatment.

SourceUniversity of Minnesota·JournalJournal of Clinical Investigation·DateOct 9, 2002

Green tea may fight allergies

Researchers identified a green tea compound that may block a key cell receptor involved in allergic responses, potentially providing an anti-allergenic effect. The study found that the compound, methylated EGCG, is more potent than previously discovered compounds and may work against various allergens.

SourceAmerican Chemical Society·JournalJournal of Agricultural and Food Chemistry·DateSep 18, 2002

Breakthrough in hormonal breast cancer therapy

Anastrozole, an aromatase inhibitor, has been shown to be more effective than tamoxifen in reducing the risk of breast cancer recurrence, hot flushes, and thromboembolic events. The treatment also reduces the incidence of endometrial abnormalities and vaginal bleeding, providing a significant benefit for postmenopausal women with early...

Behavior plays key role in disease development and control, according to 10-year prospective review

The article highlights the significant impact of behavioral factors on various diseases, including coronary heart disease, diabetes, obesity, and asthma. Research shows that negative emotions can lower immunity, while stress and depression can provoke the release of hormones that affect immune function.

SourceAmerican Psychological Association·JournalJournal of Consulting and Clinical Psychology·DateJun 23, 2002

Tobacco money – Up in smoke?

Researchers argue that NY-ELCAP cannot determine if spiral CT screening saves lives due to a lack of control group. The study's design flaw could lead to overdiagnosis and unnecessary treatment for some participants.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJun 13, 2002